BusinessChromaDex Names Dr. Matthew Roberts as a New Scientific Advisory Board MemberBy Nasdaq OMXNov 7, 2016, 11:30 AM UTC
BusinessEntia Biosciences, Inc. (OTCQB: ERGO) Receives Notification of the Grant of European Patent it has Exclusively Licensed for Identifying the Ergothioneine Transporter and its Therapeutic UsesBy Nasdaq OMXNov 2, 2016, 7:20 PM UTC
BusinessFilament BioSolutions Announces Exclusive License Agreement with Leading Academic Institutions for Beverage to Prevent Kidney StonesBy Nasdaq OMXOct 13, 2016, 11:00 AM UTC
BusinessPublished studies in humans and mice reveal how a superior vitamin B3 may play an important role in helping us enjoy longer, healthier livesBy Nasdaq OMXOct 10, 2016, 10:30 AM UTC
BusinessEntia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual MeetingBy Nasdaq OMXOct 6, 2016, 4:52 PM UTC
BusinessChromaDex Adds New AnthOrigin™ to Its Proprietary Ingredient PortfolioBy Nasdaq OMXOct 3, 2016, 10:30 AM UTC
BusinessPreliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three monthsBy Nasdaq OMXSep 26, 2016, 12:30 PM UTC
BusinessFirst Large-Scale CLARISOY™ Production Facility Scheduled to be Commissioned in Fourth QuarterBy Nasdaq OMXSep 6, 2016, 12:38 PM UTC
